In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)

Phenotypic heterogeneity inPIK3CA-related overgrowth spectrum

(2016) H. Vahidnezhad et al.   BRITISH JOURNAL OF DERMATOLOGY

CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS)

(2016) A. Martinez-Lopez et al.   CLINICAL GENETICS

Molecular Genetics of the PI3K-AKT-mTOR Pathway in Genodermatoses: Diagnostic Implications and Treatment Opportunities

(2016) Hassan Vahidnezhad et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Somatic Activating PIK3CA Mutations Cause Venous Malformation

(2015) Nisha Limaye et al.   AMERICAN JOURNAL OF HUMAN GENETICS

PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia

(2015) Laura A. Jansen et al.   BRAIN

Klippel-Trenaunay syndrome belongs to thePIK3CA-related overgrowth spectrum (PROS)

(2015) Hassan Vahidnezhad et al.   EXPERIMENTAL DERMATOLOGY

Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)

(2015) GEORGE MIHAI NITULESCU et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Lymphatic and Other Vascular Malformative/Overgrowth Disorders Are Caused by Somatic Mutations in PIK3CA

(2015) Valerie L. Luks et al.   JOURNAL OF PEDIATRICS

Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors

(2015) Daria C. Loconte et al.   PLoS One

Mosaic Neurocutaneous Disorders and Their Causes

(2015) Martino Ruggieri et al.   Seminars in Pediatric Neurology

Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome

(2015) Marjorie J. Lindhurst et al.   Scientific Reports

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092

(2015) Yi Yu et al.   PLoS One

PIK3CA-related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluation

(2014) Kim M. Keppler-Noreuil et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Clinical delineation and natural history of thePIK3CA-related overgrowth spectrum

(2014) Kim M. Keppler-Noreuil et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

PIK3CA Activating Mutations in Facial Infiltrating Lipomatosis

(2013) Reid A. Maclellan et al.   PLASTIC AND RECONSTRUCTIVE SURGERY

Somatic Mosaic Activating Mutations in PIK3CA Cause CLOVES Syndrome

(2012) Kyle C. Kurek et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Germline PIK3CA and AKT1 Mutations in Cowden and Cowden-like Syndromes

(2012) Mohammed S. Orloff et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors

(2012) Ayaz Najafov et al.   BIOCHEMICAL JOURNAL

Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly

(2012) Jonathan J. Rios et al.   HUMAN MOLECULAR GENETICS

Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA

(2012) Marjorie J Lindhurst et al.   NATURE GENETICS

De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes

(2012) Jean-Baptiste Rivière et al.   NATURE GENETICS

De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly

(2012) Jeong Ho Lee et al.   NATURE GENETICS

Somatic Activation of AKT3 Causes Hemispheric Developmental Brain Malformations

(2012) Annapurna Poduri et al.   NEURON

A Mosaic Activating Mutation inAKT1Associated with the Proteus Syndrome

(2011) Marjorie J. Lindhurst et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Activating Mutation of AKT2 and Human Hypoglycemia

(2011) K. Hussain et al.   SCIENCE

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

Molecular Mechanism of an Oncogenic Mutation That Alters Membrane Targeting: Glu17Lys Modifies the PIP Lipid Specificity of the AKT1 PH Domain†

(2008) Kyle E. Landgraf et al.   BIOCHEMISTRY

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE